PET Imaging in ALS Patients



Status:Completed
Conditions:Neurology, Neurology, Neurology, ALS
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 80
Updated:3/8/2017
Start Date:August 2013
End Date:March 2017

Use our guide to learn which trials are right for you!

Metabotropic Glutamate Receptor 5 (mGluR5) Imaging in Amyotrophic Lateral Sclerosis (ALS) Patients and Healthy Volunteers

This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and
monitoring progression of ALS, based on a well established basic science pathway, published
human autopsy data, preliminary data in ALS mutant mice, and our recently published data
using brain PET scans to image the metabotropic glutamate receptor type 5 (mGluR5) in
healthy human volunteers.


Inclusion Criteria:

- Male or female ALS patients, ranging in age from 18-80.

- Must meet El Escorial Criteria for Probable or Definite ALS.

- Disease duration >1 year, but <3 years.

- Weakness in at least two extremities.

- Forced vital capacity less than 80% and greater than 50%.

Exclusion Criteria:

- Documented orthopnea or otherwise unable to lie flat in a PET scanner for 90 minutes.

- Presence of pacemakers, aneurysm clips, shrapnel, or other implanted metallic devices
that would preclude an MRI scan.

- Absence of sufficient collateral arterial circulation for radial arterial line
placement in both wrists.

- Significant abnormalities of hepatic or renal function, or illicit substance use.

- Positive drug screen. (Subjects currently taking prescribed narcotic medication who
have a positive drug screen for this medication will not be excluded. Medication
history will be obtained during screening).

- Weighs > 350 lbs.
We found this trial at
1
site
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials